CD4 and cancer: SRA was suggested to mediate OVA-specific CD8+ T-cell proliferation in a cancer model, and SRA deficiency was found to promote the expansion and activation of cancer-specific CD8+ T lymphocytes [43]; however, it should be noted that this previous study investigated the effect of SRA on OVA-specific cytotoxic CD8+ T cells in a cancer model and not on endogenous CD4+ T cells in an autoimmune model as demonstrated in the current study.